

Tel: (256) 41- 321962 (Direct)  
(256) 41- 320385/6 (General)  
Fax: (256) 41- 320483  
Email: [directoruvri@ug.cdc.gov](mailto:directoruvri@ug.cdc.gov)



UGANDA VIRUS RESEARCH  
INSTITUTE (UVRI)  
P.O.Box 49 ENTEBBE (U)

*Our Ref:* GC/127/10/07/02  
*Your Ref:*

1<sup>st</sup> July 2010

Prof. Heiner Grosskurth, Drs. Paula Munderi, Anatoli Kamali, et-al,

RE: UVRI SEC review of an amendment to the protocol titled: **“Safety of Discontinuing Cotrimoxazole Prophylaxis among HIV Infected Adults in Uganda (COSTOP)”**

Thank you for your response to the queries addressed to you during the SEC meeting of 17<sup>th</sup> June 2010.

This is to inform you that your responses dated 30<sup>th</sup> June 2010 were reviewed and met the requirements of the UVRI Science and Ethics Committee.

UVRI SEC approval has been given for you to continue with your research. Annual progress report and request for extension should be submitted to UVRI SEC before the expiry of one year after initial date of approval i.e. by 10<sup>th</sup> March 2011.

You can now continue with your study after registration of your amendment with the Uganda National Council for Science and Technology (UNCST).

Wish you the best of luck.

Yours sincerely,

A handwritten signature in dark ink, appearing to read 'Tom Lutalo', is written over a circular stamp.

Mr. Tom Lutalo  
**Chair, UVRI SEC**

C.C     Director, UVRI  
           Secretary, UVRI SEC